Released Mar 5, 2018, after the close
10-K filed Mar 5, 2018, 64 days after period end · 0001564590-18-004394
Q4 2017 · 10-K
Revenue$1.03M$1.03M ±0.0% vs Q4 2016+0.1% vs Q3 2017
Net Income-$12.50M-$12.50M N/M vs Q4 2016N/M vs Q3 2017
EPS Diluted-$0.29-$0.29 N/M vs Q4 2016N/M vs Q3 2017
Operating Incomederived-$12,244,000N/M
Operating Cash Flowderived-$10,721,000N/M
Free Cash Flowderived-$11,518,000N/M
Margins · derived
Operating margin-1192.2%−446.9 pt vs Q4 2016
Net margin-1216.8%−443.7 pt vs Q4 2016
What the release said
The release
Same quarter
| Metric | Q4 2017 | Q4 2016 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $1.08M | — |
| Net Income | -$12.50M | -$7.94M | -$7.45M | -$6.23M |
| EPS Diluted | -$0.29 | -$0.21 | -$0.26 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR